NASDAQ · IKT
Inhibikase Therapeutics, Inc.
$1.67+$0.05 (+3.09%)
Inhibikase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.02% below the high.
Loading market information…
NASDAQ · JYNT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
The Joint Corp.’s quoted price sits in the lower half of its reported 52-week range, 31.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
The Joint Corp.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow The Joint Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers. Its business operations are structured into two main divisions: corporate-owned clinics and franchised facilities. The firm employs several strategic models for its expansion and day-to-day functioning, which include direct company ownership, various management agreements, licensing its brand to franchisees, and collaborating with regional development partners. As of March 1, 2022, the company maintained approximately 700 active locations throughout the United States. Founded in 2010, The Joint Corp. maintains its primary corporate headquarters in Scottsdale, Arizona.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 8, 2025 |
| -$0.03-50.0% vs estimate |
| $13.08M+0.43% vs estimate |
| Q4 2024 | Mar 13, 2025 | $0.060.0% vs estimate | $14.45M-50.17% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.04+2,731.58% vs estimate | $30.20M+4.16% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.67+$0.05 (+3.09%)
Inhibikase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.02% below the high.
$2.93-$0.02 (-0.68%)
SkyAI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.71% below the high.
$2.69+$0.08 (+3.07%)
Apyx Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 47.05% below the high.
$0.43+$0.02 (+5.03%)
Lucid Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.48% below the high.
$2.06+$0.03 (+1.48%)
Sera Prognostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.49% below the high.
$1.80+$0.03 (+1.69%)
CareCloud, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.76% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
$1.17+$0.02 (+1.74%)
biote Corp.’s quoted price sits in the lower half of its reported 52-week range, 60.74% below the high.
